DOT Compliance Services


Drug Free Business offers comprehensive compliance services for all U.S. Department of Transportation modal regulations (FMCSA, FAA, FTA, PHMSA, USCG, FRA). Our DOT compliance program includes:


  • DOT compliant substance abuse policies
  • DOT compliant random selection pools:
  • Drug Free Business has developed its own proprietary software to manage DOT random pool selections. Customized to the way you want it.
  • Corporate programs for you to manage a multi-location or nation-wide program in just minutes a month - no extra fees
  • Notifications reminding you to get testing done when you still have outstanding selections near end of selection period
  • DOT mandated supervisor training
  • Periodic audit reports to keep your company up to date on its compliance status

Ready to sign up now for drug testing?  Sign-me-up Form . Are you an "owner-operator" or need a DOT Consortium Pool? Sign up for DFB's DOT Consortium Pool.

Do you just have a question about drug and alcohol testing, or need some guidance? Contact Us Form

Drug Free Business also offers free live webinars to assist employers in complying with FMCSA regulations.







Changes in Federal Transportation Workplace Drug & Alcohol
Testing Programs


11/12/2017 Part 40 Final Rule - DOT Summary of Changes


   Today, November 13, 2017, the Department of Transportation (DOT) published a final rule in the Federal Register (82 FR 52229).  The rule, among other items, added four semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone).  It also added methylenedioxyamphetamine (MDA) as an initial test analyte and removed the testing for methylenedioxyethylamphetaime (MDEA).


When is the final rule effective?

     The final rule is effective January 1, 2018.


What does this mean for employees?

     You will also be tested for four semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone).  Some common names for these semi-synthetic opioids include OxyContin®, Percodan®, Percocet®, Vicodin®, Lortab®, Norco®, Dilaudid®, Exalgo®.  In addition, you will no longer be tested for MDEA.


What does this mean for employers and Consortium/Third Party Administrators (C/TPA)?

     As an employer or C/TPA, you will no longer be required to submit blind specimens to laboratories.


What does this mean for urine collectors?

     The shy bladder process has been modified so that the collector will discard any specimen provided during the collection event when the employee does not provide a sufficient specimen by the end of the three hour wait period.


What does this mean for laboratories?

   As an HHS-certified laboratory you will:

  • Add four semi-synthetic opioids: hydrocodone, oxycodone, hydromorphone; oxymorphone to your DOT testing panel;
  • Add MDA as an initial test analyte;
  • Remove testing for MDEA;
  • Add three more fatal flaws to the list of reasons when a laboratory would report a ‘rejected for testing’ specimen; and
  • Need to modify the reports [in Appendix B & C] you provide to employers and the DOT.

What does this mean for Medical Review Officers (MRO)?

     Several of your MRO drug test review processes have been modified.  For example:

  • The term ‘prescription’ has been clarified;
  • You have authority to conduct D,L stereoisomer and THC-V testing; and
  • The timing when you communicate a significant safety risk has been modified.

What does this mean for alcohol technicians?

      The list of NHTSA-approved Alcohol Screening Devices and Evidential Breath Testing Devices will appear on ODAPC’s website.

What does this mean for service agents?

  • Collectors, alcohol testing technicians, MROs, and Substance Abuse Professionals will be required to subscribe to ODAPC's list-serve at:
  • Unauthorized use of DOT-branded items (such as logos or emblems) on a service agent’s website, publications, etc., could be a basis for the DOT to initiate a Public Interest Exclusion proceeding.

What are some of the other changes to Part 40?


  • The DOT added a new section reiterating that, in the DOT testing program, only urine specimens can be collected and analyzed at HHS-certified laboratories.
  • The DOT added language further emphasizing the existing DOT prohibition on the use of DNA testing on DOT drug-testing specimens.
  • The final rule made minor modifications to certain section headings.
  • The final rule moved the list of Substance Abuse Professional certification organizations from the rule text to ODAPC's website.
  • The final rule moved the MIS instructions from Appendix H to ODAPC’s website.
  • Outdated compliance dates were removed and links were updated.
  • Appendices B, C, D, and H were updated.

Where can I find a copy of the final rule?

      You can view the final rule on ODAPC’s web site


NOTE:   This document informally summarizes some of the important effects of the rule, but it is not a substitute for the rule and should not be relied upon to determine legal compliance with the rule.  ODAPC encourages affected entities, including employers and service agents, to review the final rule.

01/23/2017 - Notice of Proposed Rulemaking


The Department of Transportation is proposing to amend its drug-testing program regulation to add four opioids (hydrocodone, hydromorphone, oxymorphone, and oxycodone) to its drug-testing panel; add methylenedioxyamphetamine (MDA) as an initial test analyte; and remove methylenedioxyethylamphetamine, (MDEA) as a confirmatory test analyte.  The proposed revision of the drugtesting panel is intended to harmonize with the revised Mandatory Guidelines established by the U.S. Department of Health and Human Services for Federal drug-testing programs for urine testing.  This proposal also adds clarification to certain drug-testing program provisions where necessary, removes outdated information in the regulations that is no longer needed, and proposes to remove the requirement for employers and Consortium/Third Party Administrators to submit blind specimens.


Note: These new, proposed rules, which include expansion of the mandatory DOT testing panels to include synthetic opioids, are not yet in effect. However, it has been reported that the measure is now in the White House for final approval. In the meantime, DOT ODAPC has instructed employers to continue using the old Custody & Control Forms.


08/08/2017  Revised Custody & Control Forms


On August 8, 2017, a newly revised Federal Custody & Control Form (CCF) was approved for use by HHS-regulated employers and service agents. However, DOT-regulated employers and their service agents are NOT permitted to use the revised CCF for testing under 49 CFR Part 40 because DOT has not yet issued a final rule authorizing testing for synthetic opioids, which are listed on the new form. DOT-regulated employers and their service agents (collectors, laboratories, Medical Review Officers) are to continue using the ‘old’ CCF until further notice from DOT’s Office of Drug and Alcohol Policy and Compliance. If the revised (2017 version) CCF is used inadvertently for a DOT test and the testing was consistent with Part 40, MROs are to verify and report the result according to Part 40.